Gianluca Sala

Has grant

Associate Professor

University of Chieti-Pescara

Italy

Research Interests

Explore related searches

Professors in Italy Professors in Immunology Immunology professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Gianluca Sala is an Associate Professor at the University of Chieti-Pescara in Italy. His research primarily focuses on biomarkers in cancer, with recent publications exploring topics such as pancreatic carcinoma, glioblastoma, and advanced colorectal cancer. Notable contributions include studies on the mitotic checkpoint kinase BUB1 and the potential therapeutic implications of extracellular vesicles. His work aims to elucidate new treatment strategies and improve therapeutic targeting in various cancer types.

Recent Grants

Grant: Close

Developing new antibody-drug conjugates (ADC)s for neuroblastoma and glioblastoma

Open Date: 2022-01-01

Close Date:

Grant: Close

Development and preclinical evaluation of a novel Antibody-Drug-Conjugate (ADC) targeting HER-3

Open Date: 2017-01-01

Close Date: 2020-01-01

Articles (18)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (22)

Simon Ameer-Beg

Professor of Optical Oncology

King's College London - Guy's Campus

UNITED KINGDOM

Gianluca Sala

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (18)

Proteomic meta-analysis unveils new frontiers for biomarkers research in pancreatic carcinoma

The mitotic checkpoint kinase BUB1 is a direct and actionable target of MYB in adenoid cystic carcinoma

Anti-LGALS3BP antibody-drug conjugate treatment induces durable and potent antitumor response in a preclinical model of adenoid cystic carcinoma

Extracellular vesicles in glioblastoma: Biomarkers and therapeutic tools

LGALS3BP is a potential target of antibody‐drug conjugates in oral squamous cell carcinoma

Visualizing Galectin-3 Binding Protein Expression with ImmunoPET

Extracellular <scp>LGALS3BP</scp> : a potential disease marker and actionable target for antibody–drug conjugate therapy in glioblastoma

HPLC-DAD validated method for DM4 and its metabolite S-Me-DM4 quantification in biological matrix for clinical and pharmaceutical applications

Widespread in vivo efficacy of The-0504: A conditionally-activatable nanoferritin for tumor-agnostic targeting of CD71-expressing cancers

HER-3 surface expression increases in advanced colorectal cancer representing a potential therapeutic target

Breast cancer in the era of integrating “Omics” approaches

Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans

BAG3 induces fibroblasts to release key cytokines involved in pancreatic cell migration

Concerted BAG3 and SIRPα blockade impairs pancreatic tumor growth

Lysosomal lipid switch sensitises to nutrient deprivation and mTOR targeting in pancreatic cancer.

MYC regulates metabolism through vesicular transfer of glycolytic kinases

Role of galectin 3 binding protein in cancer progression: a potential novel therapeutic target

Therapeutic Potential of Antibody-Drug Conjugate-Based Therapy in Head and Neck Cancer: A Systematic Review

Collaborators (22)

Simon Ameer-Beg

Arturo Sala

Fabian Flores-Borja

Miryam Perrucci

Claudia Rossi

Anna Basile

Rossano Lattanzio

VITO CARLO ALBERTO CAPONIO

RODOLFO IPPOLITI

Lorenzo Lo Muzio

Giulio Fracasso

Maria Caterina Turco

Zhengwen An

Luisa Pieroni

Francesco Giansanti

Alessandra Rosati

Andrea Morandi

Paul Barber

Marcello Locatelli

Samantha Delaney

Outi Keinänen

Mattias Andersson

Make your next move.